This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank
by Shaun Pruitt
Adding to the unusually strong performance of the Russell 2000 this year, these top performers may certainly serve as stocks to add to your watchlist
BETRNegative Net Change COGTPositive Net Change CELCNegative Net Change RGCPositive Net Change OPENPositive Net Change IWMPositive Net Change
artificial-intelligence biotechnology earnings finance inflation interest-rate investing medical oncology-screening pharmaceuticals real-estate
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
by Zacks Equity Research
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
RHHBYNegative Net Change LLYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?
by Ahan Chakraborty
LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.
NVOPositive Net Change LLYPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?
by Zacks Equity Research
Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.
NVOPositive Net Change LLYPositive Net Change WVENegative Net Change
biotechs medical pharmaceuticals
GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?
by Kinjel Shah
GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.
AZNNegative Net Change GSKPositive Net Change NVOPositive Net Change LLYPositive Net Change
pharmaceuticals
Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
by Sundeep Ganoria
ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Top Research Reports for Broadcom, Exxon Mobil & Johnson & Johnson
by Mark Vickery
Broadcom rides surging AI semiconductor demand and VMware integration strength, even as margins tighten and debt remains a drag.
JNJPositive Net Change XOMNo Net Change TRMBPositive Net Change AVGONegative Net Change SYFPositive Net Change ITICPositive Net Change APTVPositive Net Change FRDPositive Net Change
industrial-products insurance oil-energy pharmaceuticals semiconductor
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
by Ahan Chakraborty
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
by Kinjel Shah
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
pharmaceuticals
JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
by Kinjel Shah
JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.
JNJPositive Net Change PFEPositive Net Change
pharmaceuticals
Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
by Aparajita Dutta
Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
BMYNegative Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVNegative Net Change PJPPositive Net Change IHEPositive Net Change PPHPositive Net Change
etfs pharmaceuticals
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
by Kinjel Shah
Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.
SNYPositive Net Change BMYNegative Net Change NVOPositive Net Change TEVAPositive Net Change
pharmaceuticals
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?
by Kinjel Shah
Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
MRKPositive Net Change MRNAPositive Net Change CDTXPositive Net Change SMMTPositive Net Change
pharmaceuticals
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
by Zacks Equity Research
Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pharma ETF (XPH) Hits a New 52-Week High
by Sanghamitra Saha
Pharma ETF XPH hits a fresh 52-week high as healthcare shines amid AI bubble fears and slowing growth. Biotech M&A adds fuel -- can momentum hold?
XPHNegative Net Change
etfs pharmaceuticals
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
by Zacks Equity Research
Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
RDYPositive Net Change TEVAPositive Net Change SDZNYPositive Net Change
pharmaceuticals
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
by Ekta Bagri
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
BIIBNegative Net Change BMYNegative Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?
by Kinjel Shah
J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.
JNJPositive Net Change AMGNPositive Net Change TEVAPositive Net Change
pharmaceuticals
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know
by Zacks Equity Research
Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.
ANIPPositive Net Change CRMDPositive Net Change ARQTNegative Net Change PRAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
by Zacks Equity Research
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
INCYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Dec 8, 2025
by Zacks Equity Research
Companies in The News Are: WBD, NFLX, MRK, VSCO, NRG
NRGPositive Net Change MRKPositive Net Change NFLXPositive Net Change WBDNegative Net Change VSCOPositive Net Change
consumer-discretionary pharmaceuticals
Watch 5 Bigwigs in December After Double-Digit Returns Past Month
by Nalak Das
Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.
MRKPositive Net Change FCXPositive Net Change WMTPositive Net Change AMATNegative Net Change CVNAPositive Net Change
basic-materials internet-content pharmaceuticals retail semiconductor
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
by Zacks Equity Research
Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
ANIPPositive Net Change CRMDPositive Net Change ARQTNegative Net Change ABSINegative Net Change
biotechnology biotechs medical pharmaceuticals
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
by Zacks Equity Research
Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
ANIPPositive Net Change CRMDPositive Net Change CAPRNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Denali Enters Into a $275M Funding Deal With Royalty Pharma
by Ekta Bagri
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
BIIBNegative Net Change RPRXPositive Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals